Robert Hofmeister, Chief Scientific Officer at TCR2 THERAPEUTICS INC. (TCRR), sold 40,000 shares at $25.10 ($1.0M) on 2020-11-12, disclosed to the SEC on 2020-11-13.
Open-market sale of $1.0M TCRR by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.10 | 9,998 | $251K | 25.0% |
| 2 | $25.10 | 9,998 | $251K | 25.0% |
| 3 | $25.10 | 10,002 | $251K | 25.0% |
| 4 | $25.10 | 10,002 | $251K | 25.0% |
| Total | $25.10 avg | 40,000 | $1.0M | 100% |